Literature DB >> 11799093

Angiotensin II type 2 receptor counter-regulates type 1 receptor in catecholamine synthesis in cultured porcine adrenal medullary chromaffin cells.

Kazuhiro Takekoshi1, Kiyoaki Ishii, Shunsuke Shibuya, Yasushi Kawakami, Kazumasa Isobe, Toshiaki Nakai.   

Abstract

We previously showed that CGP 42112 (an angiotensin type 2 [AT(2)] agonist) markedly reduces catecholamine biosynthesis by decreasing cGMP production mediated by AT(2), a subtype of Ang II receptor that is dominantly expressed in cultured porcine chromaffin cells. To elucidate the relationship of the 2 types of Ang II receptors, angiotensin type 1 (AT(1)) and AT(2), in the synthesis of catecholamine in adrenal medullary cells, we have examined the effect of Ang II plus CV-11974 (an AT(1) antagonist that selectively simulates AT(2) stimulation) and the effect of Ang II plus PD 123319 (an AT(2) antagonist that selectively simulates AT(1) stimulation) on catecholamine synthesis. We found that Ang II reduced cGMP production via AT(2), in a similar manner to that found with CGP 42112. Stimulation of AT(1) significantly upregulated protein kinase C activity. Tyrosine hydroxylase (TH) is a rate-limiting enzyme involved in the biosynthesis of catecholamine, and this catecholamine synthesis depends both on TH enzyme activity and on the levels of TH protein after TH gene transcription. We found that AT(2) stimulation significantly inhibited TH enzyme activity, whereas AT(1) stimulation significantly upregulated TH enzyme activity. The stimulatory effect of AT(1) was completely inhibited by Ro-32-0432 (a protein kinase C inhibitor) and PD 98059 (a MAP kinase kinase-1 [MEK-1] inhibitor). Pretreatment of cells with either 8-Br-cGMP (a membrane-permeable cGMP analog) or Zaprinast (a phosphodiesterase inhibitor) abolished the inhibitory effect of AT(2) on TH enzyme activity, indicating that the stimulatory effect of AT(2) may be mediated through a reduction in cGMP concentration. Similar to the effect on TH enzyme activity, AT(2) stimulation significantly reduced TH mRNA and protein levels and net catecholamine content below basal levels, whereas AT(1) stimulation increased them. We confirmed these findings by gel mobility shift assay. Our results show that stimulation of AT(2) reduces catecholamine biosynthesis via a decrease in cGMP levels. In contrast, stimulation of AT(1) stimulates catecholamine biosynthesis through activation of PKC. Thus, we conclude that AT(1) and AT(2) have counter-regulatory roles in the synthesis of catecholamine in adrenal medullary chromaffin cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799093     DOI: 10.1161/hy1201.096816

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

1.  In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET.

Authors:  Taofeek K Owonikoko; Maria E Fabucci; Philip R Brown; Nighat Nisar; John Hilton; William B Mathews; Hayden T Ravert; Paige Rauseo; Kathryn Sandberg; Robert F Dannals; Zsolt Szabo
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

2.  Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis.

Authors:  Waheed Asghar; Ali Aghazadeh-Habashi; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2017-04-07       Impact factor: 4.473

3.  Regulation of angiotensin II type 2 receptor gene expression in the adrenal medulla by acute and repeated immobilization stress.

Authors:  Regina Nostramo; Andrej Tillinger; Juan M Saavedra; Ashok Kumar; Varunkumar Pandey; Lidia Serova; Richard Kvetnansky; Esther L Sabban
Journal:  J Endocrinol       Date:  2012-08-21       Impact factor: 4.286

4.  Effects of life-long caloric restriction and voluntary exercise on age-related changes in levels of catecholamine biosynthetic enzymes and angiotensin II receptors in the rat adrenal medulla and hypothalamus.

Authors:  Benedek Erdös; Christopher S Broxson; Tessa Landa; Philip J Scarpace; Christiaan Leeuwenburgh; Yi Zhang; Nihal Tümer
Journal:  Exp Gerontol       Date:  2007-04-24       Impact factor: 4.032

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.